Macro Finance
Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion
Bloomberg Markets·November 4, 2026·1 min read
Boehringer Ingelheim GmbH signed a licensing deal potentially worth over $7 billion with China's Sino Biopharmaceutical Limited and its subsidiaries for experimental cancer treatments. The agreement underscores growing cross-border pharmaceutical partnerships, with significant milestone payments tied to development and commercialization success.
Read at Bloomberg MarketsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.